A cannabis compound reduced bladder inflammation and pain in mice better than the standard treatment
Beta-caryophyllene, a CB2 receptor agonist found in cannabis, reduced bladder inflammation and pain in a mouse model of interstitial cystitis, performing comparably to a synthetic CB2 agonist and superior to the FDA-approved treatment DMSO.
Quick Facts
What This Study Found
Both beta-caryophyllene (BCP) and the synthetic CB2 agonist HU308 significantly reduced leukocyte adhesion in bladder venules and improved capillary perfusion when instilled directly into the bladder. BCP was comparable to HU308 and superior to DMSO (the FDA-approved treatment). Oral BCP also reduced inflammation and mechanical pain.
Key Numbers
BCP significantly reduced leukocyte adhesion in bladder venules. BCP improved capillary perfusion. Effects comparable to synthetic CB2 agonist HU308. Superior to DMSO (FDA-approved treatment). Oral BCP also effective for inflammation and pain.
How They Did This
Animal study using LPS-induced interstitial cystitis in mice. Intravital microscopy measured bladder inflammation. Behavioral testing assessed pain. Compared BCP, synthetic CB2 agonist HU308, and DMSO (standard treatment).
Why This Research Matters
Interstitial cystitis has limited treatment options and current therapies are often inadequate. BCP is a natural compound with GRAS (Generally Regarded as Safe) status found in common foods, making it a particularly accessible potential treatment candidate.
The Bigger Picture
BCP is found in black pepper, cloves, hops, and cannabis. If a dietary compound already classified as safe can outperform the standard treatment for interstitial cystitis, it could offer a low-risk therapeutic option for a condition that affects millions.
What This Study Doesn't Tell Us
Mouse model using LPS-induced cystitis may not fully represent the complex human condition. Single study without dose-response optimization. Translation from intravital microscopy endpoints to clinical outcomes is uncertain.
Questions This Raises
- ?Would BCP work in human interstitial cystitis?
- ?What is the optimal route and dose for clinical use?
- ?Could BCP be combined with existing treatments for additive benefit?
Trust & Context
- Key Stat:
- Better than FDA-approved treatment
- Evidence Grade:
- Rated preliminary because this is a single animal study, despite promising comparisons to an approved treatment.
- Study Age:
- Published in 2019.
- Original Title:
- Experimental Cannabinoid 2 Receptor Activation by Phyto-Derived and Synthetic Cannabinoid Ligands in LPS-Induced Interstitial Cystitis in Mice.
- Published In:
- Molecules (Basel, Switzerland), 24(23) (2019)
- Authors:
- Berger, Geraint, Arora, Nipun, Burkovskiy, Ian, Xia, Yanfang, Chinnadurai, Anu, Westhofen, Robert, Hagn, Georg, Cox, Ashley, Kelly, Melanie, Zhou, Juan, Lehmann, Christian
- Database ID:
- RTHC-01939
Evidence Hierarchy
Tests effects in animals (usually mice or rats), not humans.
What do these levels mean? →Frequently Asked Questions
What is beta-caryophyllene?
A natural terpene found in cannabis, black pepper, cloves, and other plants. It activates CB2 cannabinoid receptors without psychoactive effects and has GRAS (Generally Regarded as Safe) status as a food additive.
Could this help interstitial cystitis patients?
In mice, it outperformed the current standard treatment. Human studies would be needed to confirm this, but the compound's existing safety profile makes it a promising candidate for clinical trials.
Read More on RethinkTHC
- CBD-oil-quality-guide
- anxiety-medication-after-quitting-weed
- cannabis-chemotherapy-nausea
- cannabis-chronic-pain-research
- cannabis-epilepsy-CBD-Epidiolex
- cbd-anxiety-research-evidence
- cbd-for-weed-withdrawal
- cbd-vs-thc-difference
- medical-benefits-of-cannabis
- quitting-weed-before-surgery
- quitting-weed-medication-interactions
- quitting-weed-pregnancy
- quitting-weed-pregnant
- seniors-older-adults-cannabis-risks-medications
- weed-breastfeeding-THC-breast-milk
- cannabis-and-arthritis-research
Cite This Study
https://rethinkthc.com/research/RTHC-01939APA
Berger, Geraint; Arora, Nipun; Burkovskiy, Ian; Xia, Yanfang; Chinnadurai, Anu; Westhofen, Robert; Hagn, Georg; Cox, Ashley; Kelly, Melanie; Zhou, Juan; Lehmann, Christian. (2019). Experimental Cannabinoid 2 Receptor Activation by Phyto-Derived and Synthetic Cannabinoid Ligands in LPS-Induced Interstitial Cystitis in Mice.. Molecules (Basel, Switzerland), 24(23). https://doi.org/10.3390/molecules24234239
MLA
Berger, Geraint, et al. "Experimental Cannabinoid 2 Receptor Activation by Phyto-Derived and Synthetic Cannabinoid Ligands in LPS-Induced Interstitial Cystitis in Mice.." Molecules (Basel, 2019. https://doi.org/10.3390/molecules24234239
RethinkTHC
RethinkTHC Research Database. "Experimental Cannabinoid 2 Receptor Activation by Phyto-Deri..." RTHC-01939. Retrieved from https://rethinkthc.com/research/berger-2019-experimental-cannabinoid-2-receptor
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkTHC research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.